Theravance Biopharma (TBPH) EBT (2016 - 2025)
Historic EBT for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$2.9 million.
- Theravance Biopharma's EBT rose 7125.95% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.2 million, marking a year-over-year increase of 21609.45%. This contributed to the annual value of -$44.6 million for FY2024, which is 944.81% up from last year.
- Per Theravance Biopharma's latest filing, its EBT stood at -$2.9 million for Q3 2025, which was up 7125.95% from $73.2 million recorded in Q2 2025.
- In the past 5 years, Theravance Biopharma's EBT registered a high of $73.2 million during Q2 2025, and its lowest value of -$79.5 million during Q1 2021.
- In the last 5 years, Theravance Biopharma's EBT had a median value of -$14.3 million in 2022 and averaged -$19.8 million.
- Per our database at Business Quant, Theravance Biopharma's EBT crashed by 7820.97% in 2024 and then skyrocketed by 58095.39% in 2025.
- Over the past 5 years, Theravance Biopharma's EBT (Quarter) stood at -$58.0 million in 2021, then skyrocketed by 75.4% to -$14.3 million in 2022, then soared by 64.82% to -$5.0 million in 2023, then plummeted by 78.21% to -$8.9 million in 2024, then skyrocketed by 67.68% to -$2.9 million in 2025.
- Its EBT was -$2.9 million in Q3 2025, compared to $73.2 million in Q2 2025 and -$14.1 million in Q1 2025.